Última Hora: "El PP ratifica en el Congreso el recorte del 64% en el presupuesto ... - La Nueva España" Thu, 24 May 2012 03:23:13 GMT    "Las grandes empresas prevén para 2013 una recuperación ... - La Nueva España" Thu, 24 May 2012 03:22:52 GMT    "Nissan invertirá en dos años 300 millones en España - Cinco Días" Thu, 24 May 2012 00:11:41 GMT    "Otegi publica una foto que se hizo en 2011 con un pelotari y edil ... - La Nueva España" Thu, 24 May 2012 03:22:52 GMT    "Facebook sube, pero enfrenta demandas - Lanacion.com (Argentina)" Thu, 24 May 2012 05:44:01 GMT   "Rajoy ve "capital" que el BCE actúe para garantizar la ... - Europa Press" Thu, 24 May 2012 05:52:47 GMT    "La región ganaría 92 millones si se varía el Impuesto de Sociedades - El Periódico Extremadura" Thu, 24 May 2012 05:50:21 GMT    "¿Debe la UE trabajar en una salida de Grecia del euro? - El País.com (España)" Thu, 24 May 2012 05:28:51 GMT    "Los afectados por las preferentes aplauden la demanda del fiscal - La Voz de Galicia" Thu, 24 May 2012 03:02:02 GMT    "Economía frena la salida para NCG a la espera del resultado de la ... - Faro de Vigo" Thu, 24 May 2012 04:34:51 GMT      Para más noticias, haga clic aquí.

Zona de Acceso
       
       
¿Recordarme? 

Sin variación
Forest Laboratori - [Ticker: FRX]Gráfico Forest Laboratori  Noticias Forest Laboratori  Descargar Históricos de Metastock Forest Laboratori y Otros  Análisis Técnico Forest Laboratori  
Última Transacción32,930Hora de Cotización2012-05-23 - 21:00
Variación0,000 (0,000%)Rango 52 Semanas[28,470 - 40,520]
Máximo0,000Mínimo0,000
Volumen0Volumen Medio (3m)1.863.050
Demanda / OfertaN/AYieldN/A
Cierre Anterior32,930PER9,42%
Apertura0,000EPS3,57
Fecha Ex-DividendoN/AFecha DividendoN/A
Capitalización Bursátil9 Objetivo Estimado 1 Año35,980
Nota: Los datos pueden tener un retraso de algunos minutos.
Ver cotizaciones de otros activos

Intradía   5 días   1 mes   3 meses   6 meses   1 año   2 años   5 años   10 años            Utilice este gráfico en su sitio web!
Gráfico de Forest Laboratori -  [Ticker: FRX]
Cambiar para Gráfico Interactivo de Análisis Técnico de Forest Laboratori

Últimos 10 Tópicos en el Foro relacionados con Forest Laboratori:
No se han encontrado tópicos relacionados con Forest Laboratori [FRX], pero se aconseja la búsqueda en el Foro para tópicos relacionados con Forest Laboratori.

 Noticias de Forest Laboratori [FRX]:   (ordenadas por relevancia)

Forest and Almirall to Present Aclidinium Bromide Clinical Data at the ...
MarketWatch (press release)
NEW YORK, May 18, 2012 (BUSINESS WIRE) -- Forest Laboratories, Inc. (NYSE:FRX) and Almirall, SA (ALM.MC) today announced that they will present aclidinium-related data in 1 poster discussion session and 3 poster presentations at the American Thoracic ...

y más »

Ironwood and Forest to Present 17 Linaclotide-Related Abstracts at Digestive ...
MarketWatch (press release)
NEW YORK, May 14, 2012 (BUSINESS WIRE) -- Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) and Forest Laboratories, Inc. (NYSE:FRX) today announced they will present linaclotide-related data in one oral presentation and 16 poster presentations during ...

y más »

Forest and Almirall to Present Aclidinium Bromide Clinical Data at the ...
EON: Enhanced Online News (press release)
NEW YORK--(EON: Enhanced Online News)--Forest Laboratories, Inc. (NYSE: FRX) and Almirall, SA (ALM.MC) today announced that they will present aclidinium-related data in 1 poster discussion session and 3 poster presentations at the American Thoracic ...
FOREST LABORATORIES, INC. : Forest and Almirall to Present Aclidinium Bromide ...4-traders

los 4 artículos informativos »

Forest Laboratories, Inc. to Present Cariprazine and Levomilnacipran Results ...
MarketWatch (press release)
NEW YORK, May 04, 2012 (BUSINESS WIRE) -- Forest Laboratories, Inc. (NYSE:FRX) today announced it will be presenting data on two late-stage development products, cariprazine and levomilnacipran, at the American Psychiatric Association (APA) Annual ...
Forest Labs. To Present Cariprazine, Levomilnacipran Results From Phase 3 TrialsNASDAQ

los 7 artículos informativos »

Zacks Reaffirms Neutral Rating on Forest Laboratories (FRX)
Junction Report
Forest Laboratories (NYSE: FRX)'s stock had its ?neutral? rating reiterated by Zacks in a note issued to investors on Monday. They currently have a $37.00 target price on the stock. Zacks' analyst wrote, ?Forest Labs is facing tough times with its lead ...

y más »

Analyst Research on Teva Pharmaceutical Industries Limited and Forest ...
MarketWatch (press release)
... COMTEX) -- www.stockcall.com/ offers investors comprehensive research on the Drug Manufacturers - Other industry and has completed analytical research on Teva Pharmaceutical Industries Limited (NASDAQ:TEVA) and Forest Laboratories Inc. (NYSE:FRX) .

y más »

Auriga Initiates Coverage on Forest Laboratories (FRX)
Daily Political
Investment analysts at Auriga began coverage on shares of Forest Laboratories (NYSE: FRX) in a note issued to investors on Thursday. The firm set a ?hold? rating and a $36.00 price target on the stock. Shares of Forest Laboratories traded up 0.78% ...


Earnings Scorecard: Forest Labs
Zacks.com
Following the release of fourth quarter and fiscal 2012 results, most of the analysts covering Forest Laboratories (FRX - Analyst Report) have made downward revisions to their earnings estimates for fiscal 2013. The downward revision in estimates is ...

y más »

ThinkEquity Raises Price Target on Forest Laboratories (FRX)
Daily Political
Investment analysts at ThinkEquity lifted their target price on shares of Forest Laboratories (NYSE: FRX) to $40.00 in a note issued to investors on Tuesday. The firm currently has a ?buy? rating on the stock. Forest Laboratories traded down 0.69% on ...


Forest Laboratories, Inc. to Present Cariprazine and Levomilnacipran Results ...
EON: Enhanced Online News (press release)
NEW YORK--(EON: Enhanced Online News)--Forest Laboratories, Inc. (NYSE: FRX) today announced it will be presenting data on two late-stage development products, cariprazine and levomilnacipran, at the American Psychiatric Association (APA) Annual ...


Zacks Industry Outlook Highlights: Eli Lilly, Forest Labs, ViroPharma ...
PR Newswire (press release)
CHICAGO, April 27, 2012 /PRNewswire/ -- Today, Zacks Equity Research discusses the Pharmaceuticals & Biotech Industry, including Eli Lilly (NYSE: LLY), Forest Labs (NYSE: FRX), ViroPharma (Nasdaq: VPHM), Novartis (NYSE: NVS) and United Therapeutics ...

y más »

M&A: Four Health Care Stocks in Play (AMLN, FRX, STJ, EW)
Stock Traders Daily
Another drugmaker that may soon find itself to be the subject of an increasing number of takeover rumors is Forest Laboratories (NYSE: FRX). The company has been mentioned as a potential target for AstraZeneca (NYSE: AZN) as AstraZeneca begins its ...

y más »

Healthcare Sectors Showed Positive Momentum- OREX, ARNA, VVUS, DVAX, TEVA ...
eStocksDaily
... Warner Chilcott Plc (NASDAQ:WCRX) moved up +0.23%, Amarin Corporation plc (ADR) (NASDAQ:AMRN) dropped -0.86%, Forest Laboratories, Inc. (NYSE:FRX) which increased +0.74% and Ardea Biosciences, Inc. (NASDAQ:RDEA) added +0.22%.

y más »

Forbes

Best Summer Stocks And Books
Forbes
Drugmaker Forest Laboratories (FRX, 34) has a checkered past?too much of one big patent-expired antidepressant (Lexapro)?and 2010 criminal settlements and allegations. That's all in the past. The future is brighter with a great stream of 17 new and ...


Synergy Pharmaceuticals (NASDAQ:SGYP) May Be Ready To Roll
Market Playground
Ironwood, for example, already has a partner in Forest Laboratories, Inc. (NYSE:FRX), which takes them, for the most part, out of the equation as a potential buyout candidate by a deep-pocketed third party who would have to purchase two companies to ...

y más »
Para más noticias de Forest Laboratori hacer clic aquí:
Noticias de Forest Laboratori

Anchura de la Página:

 Imagen de Fondo:

Copyright@2009-2012 - BolsaES.com, todos los derechos reservados.
Foro de Bolsa Cotizaciones Noticias de Bolsa Chat de Bolsa Disclaimer Recursos para Webmasters